

# Walpole

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	26	25.4	102.4	(66.9-150.0)	Male	28	17.0	164.9	(109.5-238.3)
Female	8	9.7	82.3	(35.5-162.2)	Female	15	13.6	109.9	(61.5-181.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	5.0	100.0	(32.2-233.4)	Male	4	4.5	nc	(nc-nc)
Female	5	4.3	115.7	(37.3-270.1)	Female	8	3.7	215.8	(92.9-425.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	11	15.0	73.6	(36.7-131.6)
Female	120	100.5	119.4	(99.0-142.8)	Female	13	12.7	102.2	(54.4-174.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	3.7	136.0	(43.8-317.4)	Male	9	10.9	82.3	(37.5-156.2)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	28	30.1	93.1	(61.9-134.6)	Female	13	9.2	140.9	(74.9-240.9)
Female	36	32.0	112.5	(78.8-155.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	8	8.3	96.1	(41.4-189.4)
Male	3	6.9	nc	(nc-nc)	Female	9	9.6	93.7	(42.8-177.9)
Female	1	2.0	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	94	100.6	93.5	(75.5-114.4)
Male	1	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.7	nc	(nc-nc)	Male	6	6.0	100.2	(36.6-218.1)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	3.9	nc	(nc-nc)
Male	21	14.1	149.1	(92.2-227.9)	<b><u>Testis</u></b>				
Female	3	8.3	nc	(nc-nc)	Male	6	3.1	192.7	(70.4-419.5)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	8	4.0	198.7	(85.5-391.5)	Male	8	5.9	136.6	(58.8-269.2)
Female	0	1.2	nc	(nc-nc)	Female	20	17.6	113.5	(69.3-175.2)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	5	9.6	52.3	(16.9-122.0)	Female	26	22.8	114.0	(74.5-167.1)
Female	5	7.6	66.2	(21.3-154.4)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	348	350.4	99.3	(89.2-110.3)
Male	6	8.1	74.2	(27.1-161.6)	Female	358	349.8	102.3	(92.0-113.5)
Female	2	2.8	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	42	47.1	89.3	(64.3-120.7)					
Female	43	49.8	86.3	(62.5-116.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Waltham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	61	49.9	122.1	(93.4-156.9)	Male	37	36.5	101.5	(71.5-139.9)
Female	25	21.8	114.5	(74.1-169.0)	Female	27	32.9	82.2	(54.1-119.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	11.4	87.6	(42.0-161.2)	Male	15	9.1	165.6	(92.6-273.1)
Female	12	10.2	117.9	(60.9-206.0)	Female	4	8.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.6	nc	(nc-nc)	Male	35	32.0	109.2	(76.1-151.9)
Female	221	222.0	99.5	(86.9-113.6)	Female	32	29.0	110.3	(75.4-155.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	10	8.8	113.1	(54.1-208.0)	Male	27	23.9	113.1	(74.5-164.5)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	51	61.7	82.7	(61.6-108.8)	Female	27	20.9	129.0	(85.0-187.7)
Female	71	71.6	99.2	(77.5-125.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	19	16.6	114.2	(68.7-178.3)
Male	13	14.2	91.6	(48.7-156.7)	Female	30	21.6	139.1	(93.8-198.6)
Female	7	4.6	153.3	(61.4-315.9)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	189	206.2	91.7	(79.1-105.7)
Male	1	6.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	7	5.0	139.9	(56.0-288.2)	Male	15	12.2	123.3	(69.0-203.4)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	7	8.6	81.1	(32.5-167.2)
Male	31	29.8	104.2	(70.8-147.9)	<b><u>Testis</u></b>				
Female	12	18.6	64.4	(33.3-112.6)	Male	11	11.0	100.0	(49.9-178.9)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	7	8.2	84.9	(34.0-174.9)	Male	16	14.1	113.2	(64.7-183.9)
Female	1	2.7	nc	(nc-nc)	Female	38	44.1	86.2	(61.0-118.3)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	13	20.3	63.9	(34.0-109.3)	Female	42	50.8	82.6	(59.5-111.7)
Female	18	17.2	104.4	(61.9-165.1)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	723	728.8	99.2	(92.1-106.7)
Male	15	17.1	87.9	(49.1-144.9)	Female	791	792.4	99.8	(93.0-107.0)
Female	6	6.2	96.1	(35.1-209.2)					
<b><u>Lung and Bronchus</u></b>									
Male	112	92.6	121.0	(99.6-145.6)					
Female	116	112.4	103.2	(85.3-123.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ware

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	11.4	78.7	(35.9-149.4)	Male	7	7.4	94.7	(38.0-195.2)
Female	5	4.3	117.3	(37.8-273.7)	Female	5	6.0	84.0	(27.1-196.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	2.1	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	6	6.6	91.1	(33.3-198.3)
Female	29	42.6	68.1	(45.6-97.8)	Female	4	5.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.6	nc	(nc-nc)	Male	7	4.7	148.5	(59.5-306.1)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	14	13.5	103.4	(56.5-173.6)	Female	3	4.0	nc	(nc-nc)
Female	13	14.0	92.8	(49.4-158.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	4	3.0	nc	(nc-nc)	Male	40	41.8	95.7	(68.3-130.3)
Female	1	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	5	6.0	83.0	(26.7-193.7)	Female	8	9.8	81.6	(35.1-160.7)
Female	6	3.6	168.5	(61.5-366.7)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	1.7	nc	(nc-nc)	Female	8	9.8	81.6	(35.1-160.7)
Female	0	0.5	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	4.3	nc	(nc-nc)	Male	145	151.7	95.6	(80.7-112.5)
Female	1	3.3	nc	(nc-nc)	Female	124	151.2	82.0	(68.2-97.8)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	3	3.5	nc	(nc-nc)	Male	145	151.7	95.6	(80.7-112.5)
Female	2	1.2	nc	(nc-nc)	Female	124	151.2	82.0	(68.2-97.8)
<b><u>Lung and Bronchus</u></b>					<b><u>All Sites / Types</u></b>				
Male	22	20.3	108.1	(67.7-163.7)	Male	145	151.7	95.6	(80.7-112.5)
Female	18	21.7	82.8	(49.0-130.8)	Female	124	151.2	82.0	(68.2-97.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wareham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	40	28.2	141.8	(101.3-193.1)	Male	9	18.0	50.1	(22.9-95.2)
Female	9	9.8	91.7	(41.9-174.1)	Female	14	13.7	102.4	(56.0-171.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	5.0	nc	(nc-nc)	Male	8	4.8	166.1	(71.5-327.2)
Female	5	4.3	117.1	(37.7-273.3)	Female	1	3.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	14	15.8	88.7	(48.4-148.8)
Female	92	101.1	91.0	(73.3-111.6)	Female	8	12.9	62.2	(26.8-122.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	3.6	nc	(nc-nc)	Male	14	11.4	122.4	(66.8-205.3)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	48	32.7	146.9	(108.3-194.7)	Female	10	9.3	107.2	(51.3-197.1)
Female	33	31.4	105.1	(72.3-147.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	10	9.1	109.4	(52.4-201.2)
Male	12	7.5	160.6	(82.9-280.6)	Female	17	9.6	176.6	(102.8-282.8)
Female	2	2.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	94	108.1	86.9	(70.3-106.4)
Male	3	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	3	1.7	nc	(nc-nc)	Male	5	6.5	76.4	(24.6-178.3)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	3.7	nc	(nc-nc)
Male	21	14.7	142.5	(88.2-217.9)	<b><u>Testis</u></b>				
Female	8	8.4	94.7	(40.8-186.7)	Male	1	2.9	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	7	4.3	161.9	(64.9-333.6)	Male	3	5.8	nc	(nc-nc)
Female	5	1.3	393.2	(126.7-917.6)	Female	17	17.5	97.3	(56.7-155.8)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	15	10.2	147.2	(82.3-242.8)	Female	26	23.8	109.4	(71.5-160.4)
Female	10	7.4	135.2	(64.7-248.7)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	435	376.4	115.6	(105.0-127.0)
Male	13	8.5	152.6	(81.2-261.0)	Female	383	352.8	108.5	(97.9-120.0)
Female	7	2.8	247.8	(99.3-510.6)					
<b><u>Lung and Bronchus</u></b>									
Male	82	51.5	159.2	(126.6-197.6)					
Female	72	51.9	138.7	(108.5-174.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Warren

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	4.9	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	25	19.5	128.2	(83.0-189.3)	Female	2	2.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	6	6.0	100.2	(36.6-218.1)	Female	1	1.8	nc	(nc-nc)
Female	3	5.7	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	8	1.6	489.7	(210.9-965.0)
Male	2	1.4	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	13	20.7	62.7	(33.3-107.2)
Male	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	0.7	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	1	1.6	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	1.9	nc	(nc-nc)	Female	6	4.5	134.7	(49.2-293.3)
Female	3	1.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	55	71.1	77.4	(58.3-100.8)
Male	3	1.8	nc	(nc-nc)	Female	68	66.3	102.5	(79.6-130.0)
Female	0	0.5	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	10	9.2	109.3	(52.3-201.0)					
Female	11	9.2	120.1	(59.9-214.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Warwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	3	3.5	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	0	0.9	nc	(nc-nc)	Female	2	0.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	0	0.2	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	0	0.5	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.3	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	3	1.5	nc	(nc-nc)	Male	11	10.8	101.4	(50.6-181.5)
Female	1	1.6	nc	(nc-nc)	Female	11	11.3	96.9	(48.3-173.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	1	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	6	3.0	197.1	(72.0-429.0)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Watertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	47	38.1	123.3	(90.6-164.0)	Male	21	24.1	87.3	(54.0-133.5)
Female	11	14.9	73.9	(36.8-132.2)	Female	20	20.9	95.6	(58.4-147.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	6.9	145.1	(69.5-266.9)	Male	5	6.3	78.8	(25.4-183.8)
Female	10	6.4	156.4	(74.9-287.7)	Female	4	5.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	16	21.3	75.0	(42.8-121.8)
Female	131	143.9	91.1	(76.1-108.1)	Female	20	19.3	103.8	(63.3-160.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	5.6	125.0	(50.1-257.5)	Male	15	14.5	103.1	(57.7-170.1)
Female					Female	6	7.5	79.6	(29.1-173.3)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	40	44.0	90.9	(65.0-123.8)	Female	11	13.5	81.3	(40.5-145.5)
Female	37	48.7	76.0	(53.5-104.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	18	12.1	148.7	(88.1-235.0)
Male	8	9.5	84.2	(36.3-166.0)	Female	19	14.8	128.8	(77.5-201.1)
Female	3	3.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	125	132.7	94.2	(78.4-112.2)
Male	6	3.2	187.0	(68.3-407.0)	<b><u>Stomach</u></b>				
Female	1	2.8	nc	(nc-nc)	Male	8	8.8	90.9	(39.2-179.2)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	6	5.9	101.5	(37.1-220.9)
Male	21	19.0	110.7	(68.5-169.2)	<b><u>Testis</u></b>				
Female	9	12.3	73.4	(33.5-139.3)	Male	7	5.6	125.7	(50.4-259.1)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	6	5.4	110.3	(40.3-240.0)	Male	11	8.0	137.9	(68.7-246.7)
Female	1	1.8	nc	(nc-nc)	Female	29	27.2	106.7	(71.5-153.3)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	10	14.1	70.8	(33.9-130.3)	Female	37	32.6	113.5	(79.9-156.4)
Female	10	11.3	88.6	(42.4-162.9)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	477	491.7	97.0	(88.5-106.1)
Male	11	10.7	102.7	(51.2-183.8)	Female	484	520.6	93.0	(84.9-101.6)
Female	4	4.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	61	66.7	91.4	(69.9-117.4)					
Female	73	75.9	96.2	(75.4-120.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wayland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	15.9	69.2	(34.5-123.8)	Male	12	10.6	113.6	(58.6-198.4)
Female	4	5.5	nc	(nc-nc)	Female	15	7.9	189.4	(105.9-312.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.1	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	7	2.5	281.2	(112.7-579.4)	Female	1	2.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	13	9.3	140.3	(74.6-239.9)
Female	84	60.4	139.1	(110.9-172.2)	Female	10	7.3	136.4	(65.3-250.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.2	nc	(nc-nc)	Male	6	7.0	85.7	(31.3-186.5)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	15	18.9	79.5	(44.5-131.1)	Female	6	5.5	109.5	(40.0-238.4)
Female	14	18.0	77.8	(42.5-130.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	6	5.3	114.1	(41.7-248.4)
Male	2	4.4	nc	(nc-nc)	Female	5	5.4	92.4	(29.8-215.7)
Female	0	1.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	61	64.7	94.2	(72.1-121.0)
Male	3	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	2.1	nc	(nc-nc)
Male	5	8.9	56.1	(18.1-130.9)	<b><u>Testis</u></b>				
Female	6	4.9	123.1	(45.0-268.0)	Male	1	1.5	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	2.6	nc	(nc-nc)	Male	5	3.6	139.8	(45.1-326.3)
Female	0	0.7	nc	(nc-nc)	Female	17	10.4	163.8	(95.3-262.2)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	5	5.9	85.1	(27.4-198.5)	Female	9	14.0	64.2	(29.3-121.9)
Female	3	4.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	191	220.8	86.5	(74.7-99.7)
Male	3	5.2	nc	(nc-nc)	Female	222	204.7	108.4	(94.6-123.7)
Female	3	1.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	22	29.7	74.1	(46.4-112.2)					
Female	25	29.0	86.3	(55.8-127.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Webster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	32	18.9	168.9	(115.5-238.4)	Male	5	12.5	40.1	(12.9-93.7)
Female	10	7.7	129.4	(62.0-238.0)	Female	2	10.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	3.6	167.5	(61.2-364.5)	Male	3	3.3	nc	(nc-nc)
Female	3	3.3	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.6	nc	(nc-nc)	Male	10	10.9	91.8	(43.9-168.8)
Female	78	73.3	106.4	(84.1-132.8)	Female	8	9.9	81.1	(34.9-159.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	2.7	224.7	(82.0-489.0)	Male	4	7.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	27	22.0	122.9	(81.0-178.8)	Female	6	6.9	86.4	(31.5-188.0)
Female	32	25.7	124.6	(85.2-175.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	8	6.2	130.0	(56.0-256.3)
Male	8	5.1	156.3	(67.3-308.0)	Female	4	7.7	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	67	74.4	90.0	(69.8-114.3)
Male	4	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	5	4.4	112.9	(36.4-263.6)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	3.1	nc	(nc-nc)
Male	8	10.2	78.7	(33.9-155.1)	<b><u>Testis</u></b>				
Female	7	6.2	113.2	(45.3-233.2)	Male	1	2.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	5	3.0	168.9	(54.4-394.2)	Male	4	4.2	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	11	12.8	85.6	(42.7-153.2)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	15	7.0	213.5	(119.4-352.2)	Female	16	16.6	96.5	(55.1-156.7)
Female	10	5.9	169.1	(81.0-311.0)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	272	258.0	105.4	(93.3-118.8)
Male	5	5.9	85.4	(27.5-199.3)	Female	267	265.4	100.6	(88.9-113.4)
Female	6	2.1	280.0	(102.2-609.4)					
<b><u>Lung and Bronchus</u></b>									
Male	34	34.7	98.1	(67.9-137.1)					
Female	36	38.1	94.4	(66.1-130.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wellesley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	26	26.3	98.9	(64.6-145.0)	Male	25	16.9	147.7	(95.6-218.1)
Female	12	10.8	111.0	(57.3-193.9)	Female	27	15.7	172.0	(113.4-250.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	5.0	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
Female	3	5.1	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	20	15.0	133.1	(81.3-205.6)
Female	117	112.2	104.3	(86.2-125.0)	Female	23	14.3	160.4	(101.7-240.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	4.1	nc	(nc-nc)	Male	5	10.9	45.8	(14.8-107.0)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	15	30.5	49.1	(27.5-81.0)	Female	9	10.4	86.2	(39.3-163.6)
Female	22	35.7	61.7	(38.6-93.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	12	8.6	140.2	(72.3-244.8)
Male	3	7.0	nc	(nc-nc)	Female	6	10.7	56.1	(20.5-122.1)
Female	2	2.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	122	101.8	119.8	(99.5-143.1)
Male	1	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	5	2.4	211.9	(68.3-494.5)	Male	4	6.1	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	4	4.3	nc	(nc-nc)
Male	12	14.0	85.8	(44.3-149.8)	<b><u>Testis</u></b>				
Female	9	9.3	97.1	(44.3-184.3)	Male	3	2.8	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	4.1	nc	(nc-nc)	Male	12	5.6	214.9	(110.9-375.4)
Female	1	1.4	nc	(nc-nc)	Female	25	20.2	123.5	(79.9-182.3)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	8	9.9	80.5	(34.6-158.5)	Female	24	25.6	93.8	(60.1-139.6)
Female	13	8.7	149.7	(79.7-256.1)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	345	354.9	97.2	(87.2-108.0)
Male	9	8.0	111.8	(51.0-212.3)	Female	375	393.2	95.4	(86.0-105.5)
Female	1	3.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	22	48.1	45.8	(28.7-69.3)					
Female	37	55.7	66.4	(46.8-91.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wellfleet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	5.5	182.2	(87.2-335.2)	Male	3	3.3	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
Female	19	16.7	113.6	(68.4-177.4)	Female	2	2.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	9	6.0	150.2	(68.6-285.2)	Female	2	1.6	nc	(nc-nc)
Female	4	5.5	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	1.8	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	27	21.3	126.7	(83.5-184.4)
Male	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.7	nc	(nc-nc)
Male	1	2.7	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	2.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	1.8	nc	(nc-nc)	Female	3	4.0	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	67	71.0	94.3	(73.1-119.8)
Male	2	1.6	nc	(nc-nc)	Female	58	59.4	97.7	(74.2-126.3)
Female	1	0.5	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	4	10.3	nc	(nc-nc)					
Female	9	9.2	97.6	(44.5-185.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wendell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	3	3.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	2	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	6	5.5	109.9	(40.1-239.2)
Male	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.1	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	14	16.6	84.2	(46.0-141.3)
Male	0	0.4	nc	(nc-nc)	Female	11	11.8	93.1	(46.4-166.5)
Female	1	0.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	2	2.1	nc	(nc-nc)					
Female	3	1.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wenham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	4	4.8	nc	(nc-nc)	Male	7	3.0	235.0	(94.1-484.2)
Female	5	1.7	289.6	(93.3-675.8)	Female	4	2.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	19	17.5	108.5	(65.3-169.5)	Female	0	2.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	5.5	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
Female	6	5.7	105.9	(38.7-230.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	20	16.1	124.2	(75.8-191.9)
Female	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	2.4	nc	(nc-nc)	Female	7	4.0	176.9	(70.9-364.5)
Female	5	1.5	340.3	(109.7-794.3)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	2	1.4	nc	(nc-nc)	Male	4	8.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	7	9.0	78.1	(31.3-161.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	8.9	67.7	(24.7-147.4)	Male	4	6.5	nc	(nc-nc)
Female	3	3.2	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.9	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	10	5.7	176.4	(84.4-324.4)
Female	35	31.3	112.0	(78.0-155.8)	Female	2	4.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.1	nc	(nc-nc)	Male	0	4.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	6	11.0	54.5	(19.9-118.6)	Female	2	2.9	nc	(nc-nc)
Female	7	10.7	65.6	(26.3-135.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	2	2.5	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.1	nc	(nc-nc)	Male	23	36.1	63.7	(40.4-95.6)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	5	5.3	94.0	(30.3-219.4)	Male	1	2.2	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	0	1.4	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	1	3.5	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	Female	6	5.2	116.3	(42.5-253.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	2.9	nc	(nc-nc)	Female	4	7.1	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	17	16.1	105.3	(61.3-168.7)	Male	95	128.4	74.0	(59.9-90.5)
Female	19	16.3	116.2	(69.9-181.5)	Female	102	111.6	91.4	(74.5-111.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	8.4	119.5	(57.2-219.8)	Male	6	5.5	109.0	(39.8-237.2)
Female	3	3.4	nc	(nc-nc)	Female	2	4.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	3	4.8	nc	(nc-nc)
Female	22	32.7	67.3	(42.2-101.9)	Female	5	4.3	115.2	(37.1-268.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	0	3.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	4	9.7	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
Female	12	11.2	107.5	(55.5-187.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	5	2.3	214.3	(69.1-500.0)	Male	1	2.8	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	4	3.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	39	34.3	113.8	(80.9-155.5)
Female	0	0.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	5	4.6	108.5	(35.0-253.2)	Male	3	2.0	nc	(nc-nc)
Female	0	2.8	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	1	3.1	nc	(nc-nc)	Male	5	1.9	267.0	(86.1-623.1)
Female	3	2.5	nc	(nc-nc)	Female	3	5.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	2.6	nc	(nc-nc)	Female	8	7.5	107.1	(46.1-211.0)
Female	0	1.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	16	15.6	102.5	(58.6-166.5)	Male	113	115.7	97.7	(80.5-117.4)
Female	22	17.2	128.1	(80.3-194.0)	Female	102	117.0	87.2	(71.1-105.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	4.8	166.1	(71.5-327.3)	Male	1	3.2	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	16	20.2	79.4	(45.3-128.9)	Female	0	2.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	6	5.8	104.0	(38.0-226.5)	Female	2	1.9	nc	(nc-nc)
Female	10	7.8	128.1	(61.3-235.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	1	1.4	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	16	20.0	80.1	(45.7-130.1)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	2	2.7	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	1	1.8	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	0	3.1	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	1.6	nc	(nc-nc)	Female	2	4.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	12	8.9	135.1	(69.7-236.0)	Male	56	67.3	83.3	(62.9-108.1)
Female	15	10.9	137.6	(76.9-226.9)	Female	58	74.9	77.4	(58.8-100.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	4.5	nc	(nc-nc)	Male	5	3.2	155.8	(50.2-363.7)
Female	1	1.3	nc	(nc-nc)	Female	8	2.3	347.7	(149.7-685.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	0.9	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	18	17.5	102.7	(60.8-162.3)	Female	0	1.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	5	5.6	89.6	(28.9-209.1)	Female	2	1.5	nc	(nc-nc)
Female	2	4.5	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	1	1.5	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	19	20.8	91.3	(55.0-142.6)
Male	1	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.5	nc	(nc-nc)
Male	0	2.8	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	1.8	nc	(nc-nc)	Female	4	4.0	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	51	67.5	75.6	(56.3-99.4)
Male	0	1.6	nc	(nc-nc)	Female	52	56.1	92.6	(69.2-121.5)
Female	0	0.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	5	8.6	58.0	(18.7-135.4)					
Female	6	7.3	81.7	(29.8-177.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	30	31.8	94.4	(63.7-134.8)	Male	20	21.0	95.3	(58.2-147.2)
Female	9	12.0	74.9	(34.2-142.2)	Female	15	16.8	89.0	(49.8-146.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	6.1	113.9	(45.6-234.8)	Male	4	5.6	nc	(nc-nc)
Female	4	5.3	nc	(nc-nc)	Female	3	4.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	16	18.3	87.2	(49.8-141.6)
Female	116	120.4	96.4	(79.6-115.6)	Female	14	15.7	89.4	(48.8-150.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	9	4.4	203.4	(92.8-386.1)	Male	21	13.2	158.9	(98.3-242.9)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	34	36.9	92.1	(63.8-128.7)	Female	8	11.2	71.3	(30.7-140.5)
Female	33	39.3	83.9	(57.8-117.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	9	10.4	86.8	(39.6-164.8)
Male	14	8.5	163.9	(89.5-275.0)	Female	8	11.9	67.3	(29.0-132.6)
Female	1	2.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	108	124.4	86.8	(71.2-104.8)
Male	2	2.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	2.2	nc	(nc-nc)	Male	8	7.4	108.7	(46.8-214.2)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	6	4.7	126.8	(46.3-276.0)
Male	18	17.2	104.4	(61.8-164.9)	<b><u>Testis</u></b>				
Female	8	10.1	79.3	(34.1-156.2)	Male	4	4.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	6	5.0	120.8	(44.1-262.9)	Male	6	7.1	84.6	(30.9-184.0)
Female	1	1.5	nc	(nc-nc)	Female	17	21.5	78.9	(45.9-126.3)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	10	11.8	84.7	(40.6-155.8)	Female	27	27.6	97.8	(64.4-142.3)
Female	8	9.3	86.5	(37.2-170.4)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	408	433.7	94.1	(85.2-103.7)
Male	9	9.9	90.5	(41.3-171.8)	Female	403	426.9	94.4	(85.4-104.1)
Female	1	3.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	56	59.2	94.5	(71.4-122.8)					
Female	75	61.8	121.4	(95.5-152.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	2.5	nc	(nc-nc)	Male	4	1.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	14	7.5	187.1	(102.2-314.0)	Female	2	0.9	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	2.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	0.8	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	15	9.2	163.4	(91.4-269.5)
Male	1	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.3	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.6	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.9	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	31	31.6	98.2	(66.7-139.4)
Male	1	0.7	nc	(nc-nc)	Female	34	25.3	134.5	(93.1-188.0)
Female	0	0.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	2	4.3	nc	(nc-nc)					
Female	5	3.7	134.9	(43.5-314.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	2.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	4	1.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.5	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	11	12.2	90.3	(45.0-161.5)	Female	3	1.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	1	3.1	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	0.9	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	15	11.6	129.2	(72.2-213.1)
Male	0	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.4	nc	(nc-nc)
Male	2	1.6	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.9	nc	(nc-nc)	Male	2	0.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.9	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	41	37.5	109.3	(78.4-148.3)
Male	1	1.0	nc	(nc-nc)	Female	41	39.8	103.1	(74.0-139.9)
Female	0	0.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	2	4.7	nc	(nc-nc)					
Female	5	5.4	92.5	(29.8-215.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	20.4	83.4	(48.6-133.6)	Male	8	13.2	60.6	(26.1-119.4)
Female	8	6.7	119.2	(51.3-234.9)	Female	9	10.0	89.6	(40.9-170.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	4.0	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	11	11.9	92.6	(46.2-165.7)
Female	68	70.5	96.4	(74.9-122.3)	Female	6	8.9	67.5	(24.6-146.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	2.8	nc	(nc-nc)	Male	4	8.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	20	24.2	82.8	(50.6-127.9)	Female	4	6.5	nc	(nc-nc)
Female	30	22.8	131.3	(88.6-187.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	5	6.5	76.9	(24.8-179.4)
Male	5	5.1	97.4	(31.4-227.3)	Female	4	6.7	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	50	70.8	<b>70.6</b>	<b>(52.4-93.1)</b>
Male	2	1.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.3	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	2.8	nc	(nc-nc)
Male	14	10.6	132.1	(72.2-221.7)	<b><u>Testis</u></b>				
Female	4	5.7	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	3.0	nc	(nc-nc)	Male	8	4.5	178.2	(76.7-351.1)
Female	0	0.8	nc	(nc-nc)	Female	13	13.7	94.8	(50.5-162.2)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	5	7.8	64.0	(20.6-149.3)	Female	15	15.4	97.3	(54.4-160.6)
Female	3	5.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	202	266.8	<b>75.7</b>	<b>(65.6-86.9)</b>
Male	3	6.1	nc	(nc-nc)	Female	230	245.7	93.6	(81.9-106.5)
Female	1	1.9	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	19	36.0	<b>52.7</b>	<b>(31.7-82.3)</b>					
Female	32	32.9	97.3	(66.5-137.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	34	43.1	78.8	(54.6-110.2)	Male	23	28.0	82.1	(52.0-123.2)
Female	12	15.7	76.3	(39.4-133.4)	Female	10	22.8	44.0	(21.0-80.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	8.4	83.3	(33.4-171.6)	Male	10	7.3	137.1	(65.6-252.1)
Female	8	7.2	110.9	(47.8-218.6)	Female	4	6.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	16	24.9	64.2	(36.7-104.2)
Female	166	160.7	103.3	(88.2-120.3)	Female	19	20.7	91.7	(55.2-143.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	10	6.0	166.7	(79.8-306.5)	Male	7	17.6	39.8	(15.9-81.9)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	49	50.6	96.9	(71.7-128.1)	Female	15	15.0	100.0	(55.9-164.9)
Female	55	51.8	106.2	(80.0-138.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	12	13.9	86.2	(44.5-150.5)
Male	18	11.1	162.3	(96.1-256.4)	Female	14	15.5	90.0	(49.2-151.1)
Female	3	3.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	133	155.6	85.5	(71.5-101.3)
Male	7	3.8	185.6	(74.3-382.4)	<b><u>Stomach</u></b>				
Female	4	3.2	nc	(nc-nc)	Male	14	10.0	139.5	(76.2-234.0)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	6	6.2	96.3	(35.2-209.6)
Male	14	22.6	62.0	(33.9-104.1)	<b><u>Testis</u></b>				
Female	14	13.3	104.9	(57.3-176.0)	Male	7	6.1	115.3	(46.2-237.6)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	6.4	nc	(nc-nc)	Male	5	9.5	52.6	(17.0-122.7)
Female	1	2.0	nc	(nc-nc)	Female	17	29.6	57.4	(33.4-92.0)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	11	16.5	66.8	(33.3-119.5)	Female	39	36.7	106.2	(75.5-145.1)
Female	13	12.4	105.0	(55.9-179.6)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	494	571.4	86.5	(79.0-94.4)
Male	9	12.9	70.0	(31.9-132.8)	Female	543	567.2	95.7	(87.9-104.1)
Female	3	4.5	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	71	76.8	92.4	(72.2-116.6)					
Female	75	80.6	93.1	(73.2-116.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	19.2	78.0	(43.6-128.6)	Male	20	14.0	142.5	(87.0-220.1)
Female	2	5.8	nc	(nc-nc)	Female	16	10.6	150.9	(86.2-245.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	4.4	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
Female	4	3.3	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.6	nc	(nc-nc)	Male	13	12.3	105.3	(56.0-180.0)
Female	87	78.4	111.0	(88.9-136.9)	Female	9	8.5	105.6	(48.2-200.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	3.3	nc	(nc-nc)	Male	12	9.7	123.5	(63.7-215.7)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	22	24.5	89.8	(56.2-135.9)	Female	6	6.8	87.9	(32.1-191.2)
Female	9	19.8	45.5	(20.8-86.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male 4 5.7 nc (nc-nc)				
Female	0	1.2	nc	(nc-nc)	Female 4 5.7 nc (nc-nc)				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	83	85.4	97.2	(77.4-120.4)
Female	1	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male 6 4.8 125.0 (45.6-272.0)				
Male	13	12.0	108.2	(57.5-185.0)	Female 4 2.3 nc (nc-nc)				
Female	3	5.9	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male 2 2.9 nc (nc-nc)				
Male	4	3.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.9	nc	(nc-nc)	Male 5 5.3 94.2 (30.4-219.9)				
<b><u>Leukemia</u></b>					Female 17 16.2 105.0 (61.2-168.2)				
Male	12	7.9	151.4	(78.1-264.5)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	7	5.2	135.5	(54.3-279.3)	Female 23 17.5 131.4 (83.3-197.2)				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	7.0	nc	(nc-nc)	Male	277	288.6	96.0	(85.0-108.0)
Female	1	1.9	nc	(nc-nc)	Female	235	250.5	93.8	(82.2-106.6)
<b><u>Lung and Bronchus</u></b>									
Male	28	36.4	76.9	(51.1-111.2)					
Female	20	31.9	62.8	(38.3-97.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westhampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	2.0	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	8	6.9	115.2	(49.6-227.1)	Female	0	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	1	2.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	1	0.7	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	12	8.2	146.8	(75.8-256.5)
Male	1	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.2	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.7	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	26	28.1	92.4	(60.3-135.4)
Male	0	0.7	nc	(nc-nc)	Female	14	22.4	62.6	(34.2-105.0)
Female	0	0.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	3	3.7	nc	(nc-nc)					
Female	0	3.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westminster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	7.2	138.7	(66.4-255.2)	Male	7	5.1	138.2	(55.4-284.8)
Female	1	2.4	nc	(nc-nc)	Female	11	3.9	279.8	(139.5-500.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.2	nc	(nc-nc)	Male	8	4.5	178.9	(77.0-352.6)
Female	35	28.9	120.9	(84.2-168.2)	Female	4	3.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	15	8.7	171.5	(95.9-282.8)	Female	3	2.6	nc	(nc-nc)
Female	1	7.9	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	4	2.4	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	Female	5	2.3	217.5	(70.1-507.6)
Female	3	0.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	21	30.0	69.9	(43.3-106.9)
Male	2	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.5	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.9	nc	(nc-nc)
Male	2	4.3	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	3	2.2	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	5.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	2.8	nc	(nc-nc)	Female	7	6.6	106.1	(42.5-218.5)
Female	0	1.9	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	106	103.5	102.5	(83.9-123.9)
Male	2	2.5	nc	(nc-nc)	Female	98	95.0	103.1	(83.7-125.7)
Female	0	0.7	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	12	13.5	88.9	(45.9-155.3)					
Female	11	12.6	87.3	(43.5-156.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Weston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	18.7	64.0	(33.0-111.8)	Male	15	11.1	134.6	(75.3-222.0)
Female	5	5.2	96.6	(31.1-225.4)	Female	8	7.0	114.4	(49.3-225.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.0	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	Female	0	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	3	9.8	nc	(nc-nc)
Female	55	52.3	105.1	(79.2-136.8)	Female	6	6.7	89.5	(32.7-194.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.8	nc	(nc-nc)	Male	3	6.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	8	20.8	38.5	(16.6-75.8)	Female	2	4.9	nc	(nc-nc)
Female	16	17.2	93.1	(53.2-151.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	5	6.0	83.1	(26.8-193.8)
Male	0	4.8	nc	(nc-nc)	Female	5	5.1	97.2	(31.3-226.9)
Female	1	1.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	62	70.6	87.8	(67.3-112.6)
Male	2	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	2.1	nc	(nc-nc)
Male	5	9.1	55.0	(17.7-128.3)	<b><u>Testis</u></b>				
Female	2	4.3	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	2.8	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	6	8.6	69.8	(25.5-152.0)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	6	6.5	92.0	(33.6-200.3)	Female	5	12.0	41.8	(13.5-97.5)
Female	8	4.0	201.0	(86.5-396.1)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	175	240.8	72.7	(62.3-84.3)
Male	3	5.2	nc	(nc-nc)	Female	172	183.1	93.9	(80.4-109.1)
Female	1	1.5	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	23	34.0	67.7	(42.9-101.6)					
Female	26	26.2	99.3	(64.8-145.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	25	21.5	116.1	(75.1-171.4)	Male	11	13.5	81.4	(40.6-145.7)
Female	13	6.8	192.5	(102.4-329.2)	Female	15	9.6	155.6	(87.0-256.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.7	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
Female	0	3.0	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	8	11.8	67.9	(29.2-133.8)
Female	54	72.0	75.0	(56.4-97.9)	Female	9	8.9	100.7	(45.9-191.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	7	2.6	269.7	(108.0-555.7)	Male	6	8.5	70.9	(25.9-154.4)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	26	24.3	107.2	(70.0-157.0)	Female	4	6.6	nc	(nc-nc)
Female	24	21.7	110.7	(70.9-164.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	12	7.0	172.5	(89.0-301.4)
Male	5	5.7	87.3	(28.1-203.8)	Female	7	6.6	105.9	(42.4-218.1)
Female	3	1.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	89	83.2	106.9	(85.9-131.6)
Male	1	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.2	nc	(nc-nc)	Male	7	4.9	142.2	(57.0-293.0)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	4	2.6	nc	(nc-nc)
Male	9	11.0	81.7	(37.3-155.2)	<b><u>Testis</u></b>				
Female	6	5.9	101.3	(37.0-220.5)	Male	2	2.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	7	3.3	213.0	(85.3-438.9)	Male	7	4.3	164.1	(65.7-338.1)
Female	2	0.9	nc	(nc-nc)	Female	11	12.5	87.8	(43.8-157.1)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	10	7.6	131.0	(62.7-240.9)	Female	18	17.0	106.1	(62.9-167.8)
Female	6	5.1	117.9	(43.1-256.7)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	281	285.1	98.6	(87.4-110.8)
Male	4	6.3	nc	(nc-nc)	Female	235	247.6	94.9	(83.2-107.9)
Female	1	2.0	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	24	39.4	60.9	(39.0-90.6)					
Female	30	36.0	83.4	(56.3-119.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	15	20.6	72.7	(40.7-119.9)	Male	20	11.9	167.7	(102.4-259.0)
Female	2	7.4	nc	(nc-nc)	Female	23	9.3	248.5	(157.5-372.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.3	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	4	2.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	11	11.0	100.4	(50.0-179.6)
Female	81	68.6	118.1	(93.8-146.8)	Female	10	9.2	108.2	(51.8-199.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	2.3	nc	(nc-nc)	Male	5	7.2	69.4	(22.3-161.8)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	19	23.2	81.8	(49.2-127.7)	Female	8	6.4	124.6	(53.7-245.6)
Female	27	24.4	110.6	(72.8-160.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	7	6.4	109.6	(43.9-225.8)
Male	4	4.8	nc	(nc-nc)	Female	9	7.3	122.5	(55.9-232.5)
Female	2	1.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	66	64.0	103.2	(79.8-131.3)
Male	1	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	3.0	nc	(nc-nc)
Male	5	9.5	52.8	(17.0-123.3)	<b><u>Testis</u></b>				
Female	2	5.8	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	2.7	nc	(nc-nc)	Male	7	3.5	199.2	(79.8-410.5)
Female	0	0.8	nc	(nc-nc)	Female	14	10.9	128.7	(70.3-215.9)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	8	7.4	107.5	(46.3-211.9)	Female	13	15.3	84.9	(45.2-145.2)
Female	6	5.5	108.5	(39.6-236.1)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	234	248.3	94.2	(82.6-107.1)
Male	3	5.4	nc	(nc-nc)	Female	280	247.4	113.2	(100.3-127.2)
Female	2	2.0	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	26	34.8	74.7	(48.8-109.4)					
Female	42	36.2	116.1	(83.6-156.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Weymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	54	61.9	87.2	(65.5-113.7)	Male	35	40.1	87.3	(60.8-121.5)
Female	28	23.6	118.6	(78.8-171.5)	Female	38	33.6	113.0	(80.0-155.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	16	11.6	138.2	(78.9-224.4)	Male	12	10.7	112.0	(57.8-195.7)
Female	14	10.5	133.6	(73.0-224.2)	Female	11	9.0	121.9	(60.8-218.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	45	35.4	127.0	(92.6-170.0)
Female	235	243.4	96.5	(84.6-109.7)	Female	32	31.0	103.2	(70.6-145.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	12	9.1	132.4	(68.3-231.2)	Male	34	25.1	135.3	(93.7-189.1)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	69	72.2	95.6	(74.4-121.0)	Female	26	22.4	115.8	(75.6-169.7)
Female	88	76.9	114.4	(91.7-140.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	21	19.9	105.3	(65.2-161.0)
Male	22	16.2	135.9	(85.1-205.7)	Female	23	23.3	98.9	(62.6-148.3)
Female	2	5.0	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	196	231.8	84.5	(73.1-97.2)
Male	7	4.9	144.1	(57.7-296.9)	<b><u>Stomach</u></b>				
Female	3	4.2	nc	(nc-nc)	Male	13	14.4	90.3	(48.0-154.4)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	4	9.2	nc	(nc-nc)
Male	38	32.5	116.9	(82.7-160.5)	<b><u>Testis</u></b>				
Female	26	20.2	128.5	(83.9-188.3)	Male	5	7.7	64.7	(20.8-150.9)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	10	9.4	106.5	(51.0-195.8)	Male	15	13.3	112.6	(63.0-185.8)
Female	3	3.0	nc	(nc-nc)	Female	52	43.8	118.7	(88.7-155.7)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	21	22.9	91.7	(56.8-140.2)	Female	46	55.9	82.3	(60.2-109.7)
Female	14	18.1	77.2	(42.1-129.5)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	813	826.5	98.4	(91.7-105.4)
Male	17	18.8	90.3	(52.6-144.6)	Female	892	852.2	104.7	(97.9-111.8)
Female	6	6.8	88.3	(32.3-192.3)					
<b><u>Lung and Bronchus</u></b>									
Male	118	112.0	105.4	(87.2-126.2)					
Female	154	123.0	125.2	(106.2-146.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Whately

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	3	0.6	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	8	7.0	113.8	(49.0-224.2)	Female	0	0.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	1	2.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	4	2.0	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	5	7.6	65.4	(21.1-152.6)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	2	1.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	0	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.7	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	4	3.4	nc	(nc-nc)	Male	17	26.6	63.9	(37.2-102.3)
Female	0	3.2	nc	(nc-nc)	Female	18	23.5	76.4	(45.3-120.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Whitman

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	12.7	141.5	(83.8-223.7)	Male	8	8.9	89.8	(38.7-177.0)
Female	1	4.4	nc	(nc-nc)	Female	10	7.5	134.1	(64.2-246.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.8	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	5	7.8	63.7	(20.5-148.7)
Female	46	53.0	86.8	(63.5-115.7)	Female	8	6.2	128.3	(55.3-252.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	2.2	nc	(nc-nc)	Male	8	6.0	134.3	(57.8-264.6)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	17	15.7	108.1	(62.9-173.1)	Female	3	4.8	nc	(nc-nc)
Female	26	14.6	177.9	(116.2-260.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	6	3.6	168.5	(61.5-366.7)	Female	4	4.3	nc	(nc-nc)
Female	4	0.9	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male				
Male	3	1.2	nc	(nc-nc)	Female	41	51.4	79.8	(57.2-108.2)
Female	0	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	10	7.3	136.7	(65.4-251.3)	Female	2	1.7	nc	(nc-nc)
Female	2	4.2	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male				
Male	5	2.1	243.5	(78.5-568.3)	Female	0	2.1	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	5	5.1	97.1	(31.3-226.7)	Female	9	10.8	83.0	(37.9-157.6)
Female	2	3.7	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Female				
Male	4	4.3	nc	(nc-nc)	Female	17	12.1	140.4	(81.7-224.7)
Female	1	1.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	29	23.0	125.8	(84.3-180.7)	Female	184	177.5	103.6	(89.2-119.7)
Female	28	24.0	116.5	(77.4-168.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wilbraham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	18.5	91.8	(53.5-147.0)	Male	25	11.4	218.4	(141.3-322.4)
Female	11	7.0	157.9	(78.7-282.5)	Female	10	9.2	108.2	(51.8-199.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	3.2	157.3	(50.7-367.1)	Male	7	3.1	223.0	(89.3-459.5)
Female	2	2.9	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	13	10.3	126.8	(67.4-216.8)
Female	74	69.2	106.9	(84.0-134.3)	Female	13	9.0	145.2	(77.2-248.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.4	nc	(nc-nc)	Male	3	7.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	18	21.4	84.0	(49.8-132.8)	Female	7	6.4	109.1	(43.7-224.8)
Female	24	22.9	104.7	(67.1-155.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	9	5.9	152.2	(69.5-289.0)
Male	3	4.7	nc	(nc-nc)	Female	11	6.9	159.2	(79.3-284.8)
Female	1	1.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	71	66.3	107.1	(83.6-135.1)
Male	3	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	1.1	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	2.8	nc	(nc-nc)
Male	9	9.3	96.5	(44.0-183.2)	<b><u>Testis</u></b>				
Female	11	5.7	191.5	(95.5-342.7)	Male	1	1.6	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	2.7	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	13	11.3	115.0	(61.2-196.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	5	6.7	74.9	(24.1-174.9)	Female	17	15.9	107.2	(62.4-171.6)
Female	5	5.2	95.8	(30.9-223.7)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	236	239.3	98.6	(86.4-112.0)
Male	5	5.5	90.7	(29.2-211.7)	Female	254	243.5	104.3	(91.9-117.9)
Female	3	2.0	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	18	33.0	54.5	(32.3-86.1)					
Female	24	35.4	67.8	(43.4-100.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Williamsburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	3.3	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	3	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	1.9	262.8	(84.7-613.2)
Female	16	12.0	133.5	(76.3-216.8)	Female	2	1.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	3	4.0	nc	(nc-nc)	Female	5	1.1	463.5	(149.4-1081.8)
Female	8	3.4	235.8	(101.5-464.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	0	0.9	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	10	12.6	79.7	(38.1-146.5)
Female	1	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	0	1.8	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	0	1.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	1.1	nc	(nc-nc)	Female	4	2.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	3	5.9	nc	(nc-nc)	Male	30	44.5	67.4	(45.4-96.2)
Female	5	5.5	90.7	(29.2-211.7)	Female	56	39.9	140.3	(106.0-182.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Williamstown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	11.9	50.4	(18.4-109.7)	Male	6	7.0	86.0	(31.4-187.1)
Female	4	4.5	nc	(nc-nc)	Female	4	5.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.9	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	6	6.3	95.8	(35.0-208.5)
Female	32	36.7	87.2	(59.7-123.2)	Female	5	5.4	92.1	(29.7-214.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.1	nc	(nc-nc)	Male	1	4.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	7	13.0	53.8	(21.6-110.9)	Female	4	3.6	nc	(nc-nc)
Female	14	14.7	95.1	(51.9-159.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	3	2.9	nc	(nc-nc)	Female	2	4.5	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male				
Male	0	0.8	nc	(nc-nc)	Female	61	41.4	147.2	(112.6-189.1)
Female	1	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	3	5.5	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
Female	0	3.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male				
Male	1	1.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	5	4.1	120.8	(38.9-282.0)	Female	4	5.5	nc	(nc-nc)
Female	1	3.2	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Female				
Male	0	3.1	nc	(nc-nc)	Male	139	148.6	93.5	(78.6-110.4)
Female	1	1.2	nc	(nc-nc)	Female	115	140.6	81.8	(67.5-98.2)
<b><u>Lung and Bronchus</u></b>					<b><u>All Sites / Types</u></b>				
Male	18	21.2	85.1	(50.4-134.5)					
Female	24	21.2	113.1	(72.4-168.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wilmington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	30	21.6	138.8	(93.7-198.2)	Male	16	14.9	107.2	(61.2-174.0)
Female	12	7.6	158.0	(81.5-276.0)	Female	15	11.8	126.8	(70.9-209.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	4.5	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
Female	4	3.7	nc	(nc-nc)	Female	6	2.9	203.8	(74.4-443.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	10	13.1	76.4	(36.6-140.5)
Female	102	85.6	119.2	(97.2-144.7)	Female	9	10.3	87.0	(39.7-165.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	3.4	nc	(nc-nc)	Male	9	9.7	92.6	(42.3-175.8)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	24	25.8	93.0	(59.6-138.4)	Female	9	7.7	116.2	(53.0-220.7)
Female	23	25.2	91.3	(57.9-137.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	6	7.1	84.0	(30.7-182.7)
Male	6	6.0	99.6	(36.4-216.7)	Female	12	7.5	160.5	(82.9-280.4)
Female	1	1.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	83	87.8	94.6	(75.3-117.2)
Male	1	1.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	3	1.6	nc	(nc-nc)	Male	4	5.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	3.0	nc	(nc-nc)
Male	16	12.5	128.1	(73.2-208.1)	<b><u>Testis</u></b>				
Female	8	6.9	116.5	(50.2-229.5)	Male	1	3.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	3.5	nc	(nc-nc)	Male	8	5.4	149.4	(64.3-294.4)
Female	1	1.0	nc	(nc-nc)	Female	10	16.5	60.5	(29.0-111.3)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	11	8.3	132.5	(66.1-237.1)	Female	19	19.3	98.5	(59.2-153.8)
Female	5	6.2	80.5	(25.9-187.8)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	304	304.8	99.7	(88.8-111.6)
Male	2	7.1	nc	(nc-nc)	Female	330	290.7	113.5	(101.6-126.5)
Female	6	2.2	266.7	(97.4-580.5)					
<b><u>Lung and Bronchus</u></b>									
Male	47	40.5	116.1	(85.3-154.4)					
Female	54	39.9	135.4	(101.7-176.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Winchendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	10.8	120.7	(64.2-206.4)	Male	2	7.5	nc	(nc-nc)
Female	0	3.2	nc	(nc-nc)	Female	3	5.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.3	nc	(nc-nc)	Male	5	2.0	254.6	(82.1-594.3)
Female	0	1.6	nc	(nc-nc)	Female	5	1.2	405.3	(130.6-945.8)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	3	6.6	nc	(nc-nc)
Female	30	36.5	82.3	(55.5-117.5)	Female	7	4.4	159.6	(63.9-328.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	1.5	nc	(nc-nc)	Male	2	5.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	19	13.1	145.1	(87.3-226.7)	Female	4	3.3	nc	(nc-nc)
Female	12	10.5	114.6	(59.2-200.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	4	3.6	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	Female	5	3.1	160.9	(51.9-375.5)
Female	1	0.7	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	43	46.0	93.6	(67.7-126.1)
Male	0	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	1.2	nc	(nc-nc)
Male	2	6.3	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	3	2.9	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	1.8	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	3	7.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	5	4.2	119.4	(38.5-278.6)	Female	9	8.2	109.6	(50.0-208.0)
Female	2	2.7	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	139	155.4	89.4	(75.2-105.6)
Male	4	3.6	nc	(nc-nc)	Female	122	123.7	98.7	(81.9-117.8)
Female	0	1.0	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	19	20.4	93.1	(56.0-145.4)					
Female	23	16.9	135.7	(86.0-203.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Winchester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	34	23.1	147.5	(102.1-206.1)	Male	24	15.1	159.5	(102.1-237.3)
Female	4	10.2	nc	(nc-nc)	Female	14	13.6	103.3	(56.4-173.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	4.4	159.1	(63.7-327.7)	Male	3	4.0	nc	(nc-nc)
Female	9	4.3	209.0	(95.4-396.8)	Female	6	3.9	155.2	(56.7-337.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	14	13.2	105.9	(57.8-177.6)
Female	92	99.9	92.1	(74.3-113.0)	Female	10	13.1	76.4	(36.6-140.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	3.5	nc	(nc-nc)	Male	10	9.7	103.0	(49.3-189.4)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	24	27.2	88.3	(56.5-131.3)	Female	8	9.3	85.9	(37.0-169.2)
Female	27	34.1	79.2	(52.2-115.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	4	7.5	nc	(nc-nc)
Male	5	6.2	80.8	(26.0-188.4)	Female	6	10.2	58.8	(21.5-127.9)
Female	2	2.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	97	89.8	108.0	(87.6-131.7)
Male	1	1.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	1.6	nc	(nc-nc)	Male	2	5.4	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	4	4.2	nc	(nc-nc)
Male	15	12.5	120.3	(67.3-198.4)	<b><u>Testis</u></b>				
Female	5	8.3	60.3	(19.4-140.7)	Male	5	2.4	207.5	(66.9-484.3)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	5	3.6	139.8	(45.1-326.3)	Male	4	5.0	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	23	16.7	137.7	(87.2-206.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	9	8.7	103.8	(47.4-197.1)	Female	25	22.5	111.2	(72.0-164.2)
Female	7	7.8	89.4	(35.8-184.2)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	334	313.1	106.7	(95.5-118.8)
Male	5	7.1	70.0	(22.6-163.4)	Female	318	354.7	89.7	(80.1-100.1)
Female	0	2.9	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	41	42.1	97.3	(69.8-132.0)					
Female	40	50.6	79.0	(56.4-107.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Windsor

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	3	1.0	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	3.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	1	1.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	3	6.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.8	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Male</u></b>				
Male	0	0.3	nc	(nc-nc)	Obs	10	21.4	46.8	(22.4-86.0)
Female	0	0.0	nc	(nc-nc)	<b><u>Female</u></b>				
<b><u>Leukemia</u></b>					Obs				
Male	0	0.6	nc	(nc-nc)	7	12.4	56.7	(22.7-116.8)	
Female	0	0.2	nc	(nc-nc)					
<b><u>Liver and Intrahepatic Bile Ducts</u></b>									
Male	0	0.5	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	1	2.8	nc	(nc-nc)					
Female	1	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Winthrop

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	19.8	111.3	(69.8-168.6)	Male	18	13.0	138.1	(81.8-218.3)
Female	8	7.9	101.8	(43.8-200.6)	Female	17	11.1	153.7	(89.5-246.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	3.9	nc	(nc-nc)	Male	0	3.4	nc	(nc-nc)
Female	4	3.4	nc	(nc-nc)	Female	5	3.0	167.3	(53.9-390.3)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	15	11.4	131.4	(73.5-216.8)
Female	101	79.5	127.0	(103.4-154.3)	Female	18	10.3	175.4	(103.9-277.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.0	nc	(nc-nc)	Male	10	8.1	123.9	(59.3-227.9)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	23	23.0	100.1	(63.4-150.1)	Female	13	7.4	176.5	(93.9-301.8)
Female	22	25.7	85.6	(53.6-129.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	9	6.4	139.9	(63.8-265.5)
Male	6	5.2	115.7	(42.3-251.9)	Female	9	7.8	116.0	(52.9-220.2)
Female	1	1.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	71	74.1	95.9	(74.9-120.9)
Male	1	1.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	4	4.6	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	3.1	nc	(nc-nc)
Male	17	10.7	159.3	(92.8-255.1)	<b><u>Testis</u></b>				
Female	16	6.6	241.0	(137.7-391.4)	Male	3	2.8	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	5	3.0	166.6	(53.7-388.8)	Male	5	4.5	111.9	(36.1-261.1)
Female	1	1.0	nc	(nc-nc)	Female	12	14.4	83.5	(43.1-145.9)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	10	7.4	135.2	(64.7-248.6)	Female	28	18.2	154.2	(102.4-222.9)
Female	5	6.0	83.5	(26.9-195.0)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	304	265.9	114.3	(101.9-128.0)
Male	7	6.0	117.4	(47.0-241.9)	Female	343	280.6	122.3	(109.7-135.9)
Female	2	2.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	43	36.3	118.5	(85.7-159.6)					
Female	53	40.6	130.7	(97.9-170.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Woburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	45	42.1	106.9	(78.0-143.1)	Male	32	27.7	115.3	(78.9-162.8)
Female	16	16.4	97.8	(55.9-158.8)	Female	24	22.9	104.8	(67.1-156.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	8.1	98.3	(42.3-193.7)	Male	5	7.4	67.9	(21.9-158.4)
Female	4	7.2	nc	(nc-nc)	Female	6	6.2	96.7	(35.3-210.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	16	24.3	65.8	(37.6-106.8)
Female	175	163.6	107.0	(91.7-124.1)	Female	24	21.3	112.6	(72.1-167.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	6.1	97.9	(35.8-213.2)	Male	21	17.2	122.3	(75.7-187.0)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	59	49.2	119.8	(91.2-154.5)	Female	18	15.2	118.5	(70.2-187.3)
Female	53	53.2	99.7	(74.7-130.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	16	13.6	117.6	(67.2-191.0)
Male	12	11.1	108.4	(55.9-189.3)	Female	17	16.2	105.2	(61.2-168.4)
Female	2	3.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	132	159.5	82.7	(69.2-98.1)
Male	2	3.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	3	2.9	nc	(nc-nc)	Male	10	9.8	102.2	(48.9-188.0)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	5	6.4	78.0	(25.1-182.0)
Male	22	22.4	98.1	(61.4-148.5)	<b><u>Testis</u></b>				
Female	17	13.8	123.3	(71.8-197.4)	Male	5	5.9	84.8	(27.3-197.8)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	6.4	nc	(nc-nc)	Male	5	9.4	53.0	(17.1-123.8)
Female	3	2.0	nc	(nc-nc)	Female	31	29.6	104.9	(71.2-148.9)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	23	15.7	146.6	(92.9-220.0)	Female	43	37.4	115.0	(83.3-155.0)
Female	20	12.5	159.7	(97.5-246.6)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	586	567.9	103.2	(95.0-111.9)
Male	10	12.9	77.5	(37.1-142.5)	Female	658	580.8	113.3	(104.8-122.3)
Female	1	4.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	104	77.0	135.1	(110.4-163.7)					
Female	97	84.8	114.4	(92.7-139.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Worcester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	173	168.4	102.7	(88.0-119.3)	Male	50	111.2	45.0	(33.4-59.3)
Female	72	64.5	111.6	(87.4-140.6)	Female	46	95.5	48.1	(35.2-64.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	28	34.2	81.8	(54.3-118.2)	Male	27	28.8	93.7	(61.7-136.3)
Female	31	30.5	101.5	(68.9-144.1)	Female	17	24.4	69.7	(40.6-111.6)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	6	5.1	116.6	(42.6-253.8)	Male	100	99.5	100.5	(81.8-122.2)
Female	550	644.5	85.3	(78.4-92.8)	Female	99	85.2	116.3	(94.5-141.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	39	25.6	152.6	(108.5-208.6)	Male	68	68.7	98.9	(76.8-125.4)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	184	197.9	93.0	(80.0-107.4)	Female	63	60.9	103.5	(79.5-132.5)
Female	221	214.4	103.1	(89.9-117.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	47	54.0	87.0	(63.9-115.7)
Male	54	43.3	124.8	(93.8-162.9)	Female	56	64.0	87.4	(66.0-113.6)
Female	13	13.4	96.8	(51.5-165.5)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	533	605.8	88.0	(80.7-95.8)
Male	19	16.4	115.5	(69.5-180.4)	<b><u>Stomach</u></b>				
Female	9	14.6	61.6	(28.1-117.0)	Male	39	39.3	99.1	(70.5-135.5)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	32	26.1	122.8	(84.0-173.4)
Male	87	89.0	97.7	(78.3-120.5)	<b><u>Testis</u></b>				
Female	53	54.0	98.1	(73.5-128.3)	Male	24	27.8	86.4	(55.3-128.5)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	26	25.0	104.1	(68.0-152.5)	Male	37	38.9	95.2	(67.0-131.2)
Female	9	7.7	116.3	(53.1-220.7)	Female	115	127.2	90.4	(74.6-108.5)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	54	65.5	82.4	(61.9-107.6)	Female	172	144.6	118.9	(101.8-138.1)
Female	51	52.2	97.7	(72.7-128.4)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	2151	2247.6	95.7	(91.7-99.8)
Male	80	50.4	158.6	(125.8-197.4)	Female	2227	2315.7	96.2	(92.2-100.3)
Female	28	18.3	153.0	(101.7-221.2)					
<b><u>Lung and Bronchus</u></b>									
Male	354	299.9	118.1	(106.1-131.0)					
Female	357	324.6	110.0	(98.9-122.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Worthington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	1.7	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	4	6.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	2	2.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	9	7.0	127.9	(58.4-242.9)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.9	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Leukemia</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wrentham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	9.4	116.7	(58.2-208.9)	Male	6	7.2	83.3	(30.4-181.4)
Female	7	4.2	164.7	(66.0-339.4)	Female	8	6.2	128.3	(55.2-252.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	2.3	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	4	6.2	nc	(nc-nc)
Female	48	45.6	105.2	(77.6-139.5)	Female	0	5.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.7	nc	(nc-nc)	Male	4	5.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	15	12.1	123.7	(69.2-204.0)	Female	3	4.2	nc	(nc-nc)
Female	17	14.5	117.3	(68.3-187.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	3	3.3	nc	(nc-nc)
Male	6	2.9	205.3	(75.0-446.8)	Female	4	4.2	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	49	43.7	112.1	(82.9-148.2)
Male	0	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	1.8	nc	(nc-nc)
Male	3	6.2	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	3	3.6	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	1.7	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	6	8.3	71.9	(26.3-156.5)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	3.9	nc	(nc-nc)	Female	6	10.0	59.8	(21.8-130.1)
Female	6	3.4	176.6	(64.5-384.3)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	145	145.9	99.4	(83.8-116.9)
Male	1	3.7	nc	(nc-nc)	Female	155	156.5	99.0	(84.0-115.9)
Female	4	1.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	16	18.2	88.1	(50.3-143.1)					
Female	14	21.1	66.2	(36.2-111.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Yarmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 (run November 2015)

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	63	43.7	144.2	(110.8-184.5)	Male	49	25.2	194.2	(143.6-256.7)
Female	29	18.4	157.4	(105.4-226.1)	Female	45	20.4	220.7	(161.0-295.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	6.5	nc	(nc-nc)	Male	10	7.2	139.5	(66.8-256.7)
Female	10	6.5	154.4	(73.9-283.9)	Female	9	6.8	132.7	(60.5-251.9)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	39	22.2	175.3	(124.7-239.7)
Female	177	151.2	117.1	(100.4-135.6)	Female	17	22.2	76.6	(44.6-122.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	4.6	131.2	(47.9-285.6)	Male	21	14.9	140.8	(87.1-215.3)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	54	47.7	113.1	(85.0-147.6)	Female	14	14.6	95.8	(52.3-160.8)
Female	49	59.1	83.0	(61.4-109.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	19	13.7	138.4	(83.3-216.2)
Male	12	10.6	112.7	(58.2-196.9)	Female	20	18.4	108.8	(66.5-168.1)
Female	7	3.9	180.2	(72.2-371.3)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	192	151.0	127.1	(109.8-146.4)
Male	7	2.2	318.9	(127.8-657.2)	<b><u>Stomach</u></b>				
Female	3	2.2	nc	(nc-nc)	Male	7	9.7	72.3	(29.0-148.9)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	8	7.3	109.7	(47.2-216.1)
Male	16	20.1	79.5	(45.4-129.2)	<b><u>Testis</u></b>				
Female	14	13.7	102.4	(56.0-171.9)	Male	3	2.9	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	9	6.1	147.7	(67.4-280.4)	Male	12	7.1	169.0	(87.2-295.2)
Female	1	2.0	nc	(nc-nc)	Female	9	20.8	43.3	(19.7-82.2)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	24	14.8	162.4	(104.0-241.6)	Female	35	35.0	100.1	(69.7-139.2)
Female	14	12.8	109.8	(60.0-184.2)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	698	538.6	129.6	(120.1-139.6)
Male	11	11.5	95.6	(47.6-171.0)	Female	628	574.8	109.3	(100.9-118.2)
Female	1	4.9	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	97	77.6	125.0	(101.4-152.5)					
Female	100	91.7	109.0	(88.7-132.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;